AbbVie Inc
NYSE:ABBV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
AbbVie Inc
NYSE:ABBV
|
US |
|
G
|
Grupo Media Capital SGPS SA
SWB:GQV
|
PT |
Intrinsic Value
The intrinsic value of AbbVie Inc (ABBV) under the Base Case is 249.84 USD per share.
Compared with the current market price of 291.49 USD, the stock appears
Overvalued by 14% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What AbbVie Does
AbbVie is a pharmaceutical company that develops and sells prescription medicines. Its business is built around branded drugs for conditions such as immune disorders, cancer, eye disease, and other serious illnesses. It also works on research and development to create new treatments and support its long-term drug portfolio.
- Headquarters
- United States of America US
- Employees
- 57 000
- IPO date
- Jan 2, 2013
AbbVie has a wide economic moat
Patents prevent rivals from copying AbbVie’s protected medicines and competing mainly on price. Protection across several treatments helps the company defend its profits without relying on a single drug.
Read the full moat analysis
Revenue & Expenses Breakdown
AbbVie Inc
Earnings Waterfall
AbbVie Inc
The intrinsic value for AbbVie Inc (ABBV) under the Base Case is 249.84 USD.
Compared with the current market price of 291.49 USD, the stock appears Overvalued by 14% .
